TI-CH, Updates on dostarlimab, ventoclax, & zongertinib
May 01, 2025•12 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This episode summarizes recent updates on:
Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361)
Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512)
Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700)
Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)
For the best experience, listen in Metacast app for iOS or Android